Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Pavlides Group: Quantitative MR and liver disease

  • Cardiovascular and Metabolic Medicine
  • Division of Cardiovascular Medicine

Our group investigates how MR techniques can be used to improve the care of patients with liver disease. The scope of our work is broad and ranges from evaluation of mature MR techniques in large multicentre studies, to proof-of-concept studies using new methods, or new clinical applications of existing technologies.

Composite image of MRI images

Our team

Recent publications

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Journal article

Pennisi G. et al, (2026), Hepatology, 84

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Journal article

Pavlides M. et al, (2026), Nat Med

Editorial: Prediction of Survival in Hepatocellular Cancer—Rise and Fall of the Machines

Journal article

Pavlides M., (2026), Alimentary Pharmacology & Therapeutics

Lowering the bar? Noninvasive tests for identifying significant fibrosis in metabolic dysfunction-associated steatotic liver disease.

Journal article

Pavlides M. and Appiah E., (2026), Pol Arch Intern Med, 136

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin

Journal article

Poole E. et al, (2026), American Journal of Transplantation, 26, 1339 - 1348